Compare Cloudflare Inc (NET) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs TG Therapeutics Inc — how do they compare? Cloudflare Inc trades at $271.31 (market cap $96.69B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Cloudflare Inc is far larger — about 11.7× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| NET | TGTX | |
|---|---|---|
Market Cap | $96.69B | $8.26B |
Sector | Technology | Health |
52-Week High | $281.69 | $59.06 |
52-Week Low | $160.16 | $26.39 |
Enterprise Value | $96.05B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $272.20, down 1.95% over 24 hours, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats but remains unprofitable, with a negative net income margin of -3.72% despite robust revenue growth to $2.17 billion in 2025. Operating cash flow improved to $603 million, though high valuation multiples like P/S of 40.96 and EV/EBITDA of 696.61 reflect premium pricing. Recent news highlights institutional interest and cybersecurity sector tailwinds.
Outlook is cautiously optimistic given analyst consensus of 72.5% buy ratings and a $271 price target near current levels. Key opportunities include AI-driven cybersecurity demand and revenue momentum, but risks encompass persistent losses, elevated debt, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
